Meningococcal B (MenB) vaccination programme

Documents relating to the new meningococcal B (MenB) vaccination (Bexsero®) programme starting from 1 September 2015.

Meningococcal disease is caused by invasive infection with the bacterium Neisseria meningitidis, also known as the meningococcus.

There are 12 identified capsular groups of which groups B, C, W and Y were historically the most common in the UK.

The new MenB vaccine (Bexsero®) will protect against meningococcal disease capsular group B. The vaccine will be added to the childhood immunisation programme as part of the routine schedule in England from 1 September 2015.

Data and reports on the uptake of the MenB vaccine for England are published by UK Health Security Agency.

Immunisation patient group direction (PGD) templates are available for authorisation and adoption to provide NHS routine immunisation services.

Guidance for healthcare professionals

Training for healthcare professionals

The Meningococcal B vaccination for infants aged from 8 weeks training slideset is available to download.

Posters and leaflets

Programme documents

Published 30 June 2015
Last updated 12 July 2021 + show all updates
  1. Added link to the Meningococcal B vaccination for infants aged from 8 weeks training slideset.

  2. Added information on immunisation patient group direction (PGD) templates.

  3. Addition of link to MenB vaccine coverage estimates

  4. Additional information added regarding MenB and Paracetamol

  5. Added training guide for healthcare professionals.

  6. Added 2 guides for parents on meningitis and septicaemia caused by meningococcal group B disease.

  7. First published.